Our Story
Tackling twin scourges of humanity
Humanity is continuously challenged by global disease burden from AMR, cancers and covid. Available therapies are unable to address many of these issues. We are a group of highly experienced scientists with a single focus agenda to provide novel solutions to these health threats.
New antibacterial (AB), antiviral (AV) and immuno-oncology (IO) interventions are urgently needed.
Our Therapy Areas
Immuno-Oncology
Stepping up Immunotherapy to the next level:
Tapping the Tumor Microenvironment
Our research programs focus on discovering affordable, differentiated, small molecule therapeutics for highly hypoxic tumors where adenosine plays a pivotal role in creating an immunosuppressive and tumor promoting environment.
Antibacterial Agents
Discovery of novel antibacterial agents:
Innovative solutions to combat AMR
Our solutions are products of sophisticated technologies with the potential to cover a broad range of priority pathogens in the syndromes of high unmet need, addressing many serious hospital and community infections and combating a broad spectrum of biothreat pathogens.
Project Portfolio
A key gap in the recently approved drugs, as well as those in late-stage pipeline, is the lack of oral options that cover Gram-Negative and Gram-Positive microbial infections. An intravenous and oral drug product will address the treatment of Gram-Negative and Gram-Positive infections implied in HABP/VABP, CABP, uUTI, cUTI, and other enteric infections.
Modulating the immune system through a small molecule approach offers several unique advantages that are complementary to, and potentially synergistic with, biologic modalities and are poised to significantly extend the scope of immuno-oncology applications and enhance the opportunities for combination with tumour-targeted agents and biologic immunotherapies.
Pipeline
Our pipeline consists of targeted small molecules for the treatment of multidrug-resistant microbial infections and hypoxic, immunosuppressed, refractory solid tumors.
About Us
Bugworks was set up in 2014 and incubated in C-CAMP, Bangalore. The core scientific team comes with a combined experience of over 200 years in Drug Discovery. Bugworks engages with multiple, globally reputed partners to propel its breakthrough broad-spectrum assets.
News & Announcements
From Cells to Molecules to Products – an in-depth video on CCAMP done by Pallava Bala for India Science. Bugworks is one of the six companies to be highlighted.
December 15, 2021 Published in Indiascience.com
Bugworks Research Inc. CSO Dr. Santanu Datta underscores need for a Bayh-Dole like Act to propel research commercialization
November 15, 2021 Published in Pharmabiz.com
Bugworks Research starts first human dose study to treat critical bacterial infections – ETHealthWorld
November 10, 2021 Published in ETHealthworld.com
Bugworks Research begins first in human phase 1 study of BWC0977 to treat critical bacterial infections
November 9, 2021 Published in Pharmabiz.com
